EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

The prevention of aminoglycoside resistance by the use of amikacin as the primary hospital aminoglycoside






Advances in Therapy 4(1): 33-39

The prevention of aminoglycoside resistance by the use of amikacin as the primary hospital aminoglycoside

The extensive use of gentamicin or tobramycin has resulted in widespread aminoglycoside nationally. Several investigators have suggested using amikacin as the primary hospital aminoglycoside to decrease aminoglycoside resistance and/or preserve the usefulness of aminoglycoside antibiotics. To determine the relationship of aminoglycoside usage to the development of aminoglycoside resistance in a 550 bed university affiliated community hospital, a prospective surveillance program was initiated in 1980. Gentamicin was used as the primary hospital aminoglycoside during the initial five-month baseline (1980). From 1981 to 1986 amikacin was used as the primary hospital aminoglycoside because of its favorable cost benefit ratio, therapeutic effectiveness, superior pharmacokinetic profile, and to prevent the emergence of aminoglycoside resistant gram-negative bacilli. Gram-negative isolates obtained during the baseline period were tested for amikacin susceptibility and all gram-negative organisms isolated during the amikacin surveillance phase were tested for susceptibility to amikacin, gentamicin, and tobramycin. Only 1% (12 of 1,250) of the organisms isolated during the baseline period were resistant to amikacin. After five years of general use, overall aminoglycoside resistance of gram-negative aerobic bacilli has not increased in our institution. The results of this study support the findings of others demonstrating that the routine use of amikacin does not promote aminoglycoside resistance. Morever, the general use of amikacin does not decrease the sensitivity of amikacin against nosocomial gram-negative bacilli. The results of this study also suggest that the use of amikacin as the primary hospital aminoglycoside may prevent the emergence of widespread aminoglycoside resistance to gentamicin, tobramycin, and amikacin.


Accession: 006740589



Related references

Saavedra S.; Ramirez Ramirez C.; Urschell W.; Duran D.; Rullan M.; Torres S.; Vera D.; Ramirez Ronda C.H., 1991: Susceptibility of escherichia coli pseudomonas aeruginosa and klebsiella pneumoniae to aminoglycoside after 7 years of amikacin use as the primary aminoglycoside in a large teaching hospital. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 31: 325

Miller, G.H.; Sabatelli, F.J.; Hare, R.S.; Glupczynski, Y.; Mackey, P.; Shlaes, D.; Shimizu, K.; Shaw, K.J., 1997: The most frequent aminoglycoside resistance mechanisms--changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. The aminoglycoside resistance mechanisms revealed by two surveys in Europe and other countries have been compared to those revealed in earlier studies. Mechanisms have become more complex in all bacterial groups. In Providencia, Serratia, Pseudomo...

Miller, G.H.; Sabatelli, F.J.; Naples, L.; Hare, R.S.; Shaw, K.J., 1995: The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin--a new broad-spectrum aminoglycoside. The Aminoglycoside Resistance Study Groups. Aminoglycoside resistance mechanisms from recent studies were compared with those found in earlier studies in the USA and Europe for three pathogen groups. Among Citrobacter-Enterobacter-Klebsiella, four single mechanisms (AAc(3)-II, AAC(3)-I, ANT...

Vanhoof, R.; Hubrechts, J.M.; Nyssen, H.J.; Roebben, E., 1988: Three-year survey of amikacin use and aminoglycoside resistance in a general hospital in Belgium. The aim of the study was to evaluate the effect of intensive use of amikacin on the resistance levels to amikacin, gentamicin, tobramycin, netilmicin and dibekacin. The base-line resistance in the preamikacin phase (three months of amikacin use le...

Vanhoof, R.; Hubrechts, J.M.; Roebben, E.; Claeys, M.; Nulens, E.; Nyssen, H.J.; Van Haeverbeek, M.; Van Gysel, J.P., 1986: A one year survey on the epidemiology of aminoglycoside resistance in a general hospital: influence of amikacin. In a 15 month period we have studied the epidemiology of aminoglycoside resistance in a general hospital. We determined the effect of preferential amikacin usage on the resistance levels of amikacin, gentamicin, tobramycin, netilmicin and dibekaci...

Culebras, E.; Martínez, J.L., 1999: Aminoglycoside resistance mediated by the bifunctional enzyme 6'-N-aminoglycoside acetyltransferase-2"-O-aminoglycoside phosphotransferase. The expression of the bifunctional aminoglycoside inactivating enzyme 6'-N-aminoglycoside acetyltransferase-2"-O-aminoglycoside phosphotransferase is the most important mechanism of high-level aminoglycoside resistance in Staphylococcus...

Gerding, D.N.; Larson, T.A.; Hughes, R.A.; Weiler, M.; Shanholtzer, C.; Peterson, L.R., 1991: Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. For 10 years the 700-bed Minneapolis Veterans Affairs Medical Center has conducted a policy of carefully controlled aminoglycoside usage and monitoring of resistance of over 25,000 aerobic and facultative gram-negative bacillary isolates to the am...

Ku, N.Su.; Choi, J.Yong.; Yong, D.; Kim, J.Myung.; Lee, K., 2013: Correlations between aminoglycoside consumption and aminoglycoside resistance in Gram-negative bacteria at a tertiary-care hospital in South Korea from 2001 to 2011. International Journal of Antimicrobial Agents 41(4): 394-395

Hubrechts J M.; Vanhoof R.; Roebben E.; Claeys M.; Nulens E.; Vanhaever Beek M.; Van Gysel J P., 1985: Effect of amikacin usage on the epidemiology of aminoglycoside resistance in a general hospital a 2 year prospective surveillance study. Abstracts of the Annual Meeting of the American Society for Microbiology 85: 385

Inouye, S.; Niizato, T.; Shomura, T.; Kitasato, I., 1989: Nephrotoxicity of dactimicin, a novel pseudo-disaccharide aminoglycoside possessing the N-formimidoyl group, compared with that of astromicin, amikacin and other aminoglycoside antibiotics in animals. The nephrotoxicity of dactimicin, the first aminoglycoside possessing the N-formimidoyl group, was compared with that of astromicin and, in part, amikacin, ribostamycin, kanamycin and gentamicin as reference aminoglycoside antibiotics. When a dose...